CliffBio
small molecule

THALOMID

THALIDOMIDE

Loss of exclusivity—loss of exclusivity
CompanyBristol Myers Squibb →See this company's full patent-cliff portfolio

Drug detail

Brand nameTHALOMID
Active ingredientTHALIDOMIDE
Strength200MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 2003
Marketing statusRX

More from Bristol Myers Squibb

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

THALOMID patent cliff — loss of exclusivity — | CliffBio